ProCE Banner Activity

Immunotherapy-Based Combinations as (Neo)Adjuvant Treatment in High-Risk HCC

Slideset

Slides from a live 2024 ASCO satellite symposium, covering the recent developments in the use of (neo)adjuvant treatments in patients with high-isk early HCC, including the use of molecular biomarkers, clinical trial updates for (neo)adjuvant immunotherapy, and strategies for determining early HCC at high risk of recurrence following ablation or resection.

Released: May 29, 2024

Expiration: May 28, 2025

Share

Faculty

Mark Yarchoan

Mark Yarchoan, MD

Associate Professor of Medical Oncology
Division of GI Malignancies
Sidney Kimmel Comprehensive Cancer Center
Johns Hopkins University
Baltimore, Maryland

Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner

Supporters

Supported by an educational grant from AstraZeneca.

AstraZeneca